Scientists advance understanding of herpesvirus infection

April 12, 2017, NIH/National Institute of Allergy and Infectious Diseases
The left image shows typical HSV reactivation (red) from latency in neurons. On the right, viral reactivation is stimulated by compounds that activate the HCF-1 binding partners. Credit: NIAID

Herpes simplex virus (HSV) infections last a lifetime. Once a person has been infected, the virus can remain dormant (latent) for years before periodically reactivating to cause recurrent disease. This poorly understood cycle has frustrated scientists for years. Now, National Institutes of Health (NIH) scientists have identified a set of protein complexes that are recruited to viral genes and stimulate both initial infection and reactivation from latency. Environmental stresses known to regulate these proteins also induce reactivation.

Globally, the World Health Organization estimates that one-half billion people are infected with HSV-2 while two-thirds of the population are infected with HSV-1. These viruses cause human diseases ranging from oral cold sores to genital lesions to serious eye conditions that can lead to blindness. In infants, HSV can cause neurological and developmental problems. People infected with HSV also have an enhanced risk of acquiring or transmitting (HIV).

Scientists at NIH's National Institute of Allergy and Infectious Diseases previously made progress toward understanding the role of cellular protein HCF-1 in initiating HSV infection and reactivation. HCF-1 and associated proteins are recruited to the viral genome to enable the virus to replicate and spread. This previous work identified targets for the development of therapeutics to suppress infection and reactivation.

Their latest work, with collaborators from Princeton University, identifies new HCF-1 protein complexes that play additional roles in initiating viral infection and reactivation. The scientists found they could reactivate latent HSV in a mouse model using compounds that turn on components of these HCF-1 protein complexes. Interestingly, some of these HCF-1-associated proteins also are involved in HIV reactivation from latency.

The researchers are continuing to investigate the protein complexes involved in promoting HSV gene expression, infection, and reactivation from latency. Identifying these complexes and understanding the mechanisms by which they function can potentially reveal additional targets for the development of new therapeutics.

Explore further: HBV reactivation seen with DAA treatment of chronic hep C

More information: Roberto Alfonso-Dunn et al, Transcriptional Elongation of HSV Immediate Early Genes by the Super Elongation Complex Drives Lytic Infection and Reactivation from Latency, Cell Host & Microbe (2017). DOI: 10.1016/j.chom.2017.03.007

Related Stories

HBV reactivation seen with DAA treatment of chronic hep C

March 13, 2017
(HealthDay)—For patients with chronic hepatitis C (CHC) treated with direct-acting antivirals (DAAs), hepatitis B virus (HBV) reactivation may occur in those with current HBV infection, according to a study published online ...

Scientists describe new herpes treatment strategy

December 3, 2014
Scientists have developed a novel treatment approach for persistent viral infections such as herpes.

Stress wakes up sleeping herpes viruses – but how?

February 24, 2016
Hiding their DNA genome inside the nuclei of the infected cells, the herpes viruses establish a lifelong infection in humans. Poorly defined stress conditions are known to wake up these parasites from their latent phase and ...

Short-course tocilizumab may up hep B reactivation in RA

February 13, 2017
(HealthDay)—For patients with rheumatoid arthritis (RA), one to three doses of tocilizumab may increase the risk of hepatitis B virus (HBV) reactivation, according to a study published online Feb. 3 in the International ...

Designed drug candidate significantly reduces HIV reactivation rate

July 8, 2015
HIV-infected patients remain on antiretroviral therapy for life because the virus survives over the long-term in infected dormant cells. Interruption of current types of antiretroviral therapy results in a rebound of the ...

Nanoparticle exposure can awaken dormant viruses in the lungs

January 16, 2017
Nanoparticles from combustion engines can activate viruses that are dormant in in lung tissue cells. This is the result of a study by researchers of Helmholtz Zentrum München, a partner in the German Center for Lung Research ...

Recommended for you

Experimental vaccine shows promise in preventing TB

September 25, 2018
(HealthDay)—Tuberculosis remains the most lethal of infectious diseases worldwide, killing more than 1.6 million people a year. But researchers say a new vaccine might prevent half of full-blown illnesses in infected people ...

Researchers seek vaccine for 'traveler's diarrhea'

September 25, 2018
Every year, millions of people have vacations and business trips ruined when they succumb to "traveler's diarrhea" during their journeys. A major cause of traveler's diarrhea is bacteria called Enterotoxigenic E. coli, or ...

Many doctors in India miss TB signs: study

September 25, 2018
Many private sector doctors in India miss the signs of tuberculosis and therefore provide patients inadequate treatment, according to a new study published Tuesday involving people hired to act out the symptoms.

New way of determining treatment for staph infections cuts antibiotic use

September 25, 2018
Using a clinical checklist to identify eligible patients, doctors were able to shorten the antibiotic duration for patients with uncomplicated staphylococcal bloodstream infections by nearly two days, Duke Health researchers ...

Breakthrough in designing a better Salmonella vaccine

September 24, 2018
UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing ...

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

3 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

travispaul309
1 / 5 (1) Apr 18, 2017

In 2003 I was told I had gotten hepatitis B. I had some flu-like symptoms. I went to my doctor, who did blood work, and then informed me that I had the Hepatitis B Virus. I was given medications for it,but no cure. After using the herbal medicine i purchased from perfecthealthherbalmedicinehome i was totally cured of Hepatitis B Virus,my doctor confirmed that I don't have it anymore,december 2016 i purchased another herbal medicine cure for My mother, she was diagnosed of pulmonary fibrosis. she had cough. my mother noticed that she was slowing down. she was always active. she was a soloist in the choir and was having a hard time singing. she was hospitalized and they did a CAT scan and found the fibrosis,so i purchased pulmonary fibrosis herbal medicine,she was cured within 6 weeks of usage.my family doctor confirm my mother is pulmonary fibrosis free. Am so happy me and my mother are living normal life again,all thanks to perfecthealthherbalmedicinehome..contact perfecthealthherba
travispaul309
1 / 5 (1) Apr 18, 2017
so i purchased pulmonary fibrosis herbal medicine,she was cured within 6 weeks of usage.my family doctor confirm my mother is pulmonary fibrosis free. Am so happy me and my mother are living normal life again,all thanks to perfecthealthherbalmedicinehome..contact perfecthealthherbalmedicinehome via website. (perfecthealthherbalmedicine @ gmail . com)
(www . perfecthealthherbal . weebly . com)
barakn
not rated yet May 11, 2017
Is there a disease your family has contracted? Or are you just a spammer?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.